Prostate Cancer Excellence Forum

Prostate Cancer

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Eleni Efstathiou, MD, Houston Methodist Cancer Center

Videos

Niraparib Plus Abiraterone and Prednisone for Patients With Castration-Resistant Prostate Cancer and HRR Alterations

02/27/2023

At 2023 ASCO Genitourinary Cancers Symposium, Eleni Efstathiou, MD, shared phase 3 data which support the use of niraparib with abiraterone acetate and prednisone among patients with metastatic castration-resistant prostate cancer and BRCA...

At 2023 ASCO Genitourinary...

02/27/2023

Oncology

Scott Tagawa, MD, Weill Cornell Medicine

Videos

Anti-PSMA Salvage Radio-Immunotherapy for Castration-Resistant Prostate Cancer

02/16/2023

Scott Tagawa, MD, presents results from a phase 2 study evaluating anti-PSMA salvage radio-immunotherapy for patients with high-risk non-metastatic castration-resistant prostate cancer.

Scott Tagawa, MD, presents...

02/16/2023

Oncology

Srikala Sridhar, MD, Princess Margaret Cancer Center

Videos

Impact of COVID-19 on Treatment of Patients With Metastatic Hormone Sensitive Prostate Cancer

12/20/2022

Srikala Sridhar, MD, shares insights from a study investigating how metastatic hormone sensitive prostate cancer care has changed during the COVID-19 pandemic.

Srikala Sridhar, MD, shares...

12/20/2022

Oncology

Quiz

Quiz: Olaparib Added to Abiraterone for Metastatic Castration-Resistant Prostate Cancer

11/30/2022

True or False: In the phase 3 PROpel study, the addition of olaparib to abiraterone improved the radiographic progression-free survival of patients with metastatic castration-resistant prostate cancer, compared to abiraterone alone.

True or False: In the phase 3...

11/30/2022

Oncology

Ana Aparicio, MD, MD Anderson Cancer Center

Videos

Treatment Approaches for Aggressive Variants of Metastatic Castration-Resistant Prostate Cancer

11/10/2022

Ana Aparicio, MD, discusses aggressive variants of metastatic castration-resistant prostate cancer, with a focus on treatment approaches for patients with androgen-indifferent disease.

Ana Aparicio, MD, discusses...

11/10/2022

Oncology

Stephane Oudard, MD, Hôpital Européen Georges-Pompidou

Videos

Adapted Cabazitaxel Schedule Reduces Neutropenic Complications in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer

11/10/2022

Stéphane Oudard, MD, reports results from a phase 3 trial demonstrating that an adapted schedule of cabazitaxel reduces neutropenic complications seen in elderly patients with metastatic castration-resistant prostate cancer without...

Stéphane Oudard, MD, reports...

11/10/2022

Oncology

Fred Saad, MD, University of Montréal Hospital Center

Videos

Olaparib Prolongs Radiographic PFS vs Placebo in Metastatic Castration-Resistant Prostate Cancer Across Subgroups

10/18/2022

Fred Saad, MD, discusses findings from a biomarker analysis of the phase 3 PROpel trial investigating abiraterone plus olaparib vs abiraterone plus placebo for patients with metastatic castration-resistant prostate cancer.

Fred Saad, MD, discusses...

10/18/2022

Oncology

Christian Rothermundt, MD, Kantonsspital St Gallen

Videos

Enzalutamide Plus Metformin Conveyed No Benefit for Disease Control Rate of Patients With Metastatic Castration-Resistant Prostate Cancer

10/12/2022

Dr Christian Rothermundt reviews the results of a phase 2 trial presented at the 2022 ESMO Congress, which demonstrated that adding metformin to enzalutamide conveyed no benefit for disease control rate of patients with metastatic...

Dr Christian Rothermundt reviews...

10/12/2022

Oncology

Evan Yu, MD, Fred Hutchinson Cancer Center

Videos

Pembrolizumab Plus Olaparib Conveyed No Survival Benefit in Metastatic Castration-Resistant Prostate Cancer

09/29/2022

Evan Yu, MD, reviews the results from a phase 3 trial examining pembrolizumab plus olaparib in patients with heavily pretreated castration-resistant prostate cancer, demonstrating no improvement in survival compared to abiraterone or...

Evan Yu, MD, reviews the results...

09/29/2022

Oncology

Joseph Renzulli, MD, Yale School of Medicine

Videos

Enzalutamide Reduces Risk of Disease Progression in Low- and Intermediate-Risk Prostate Cancer

09/12/2022

Joseph Renzulli, MD, discusses findings from the phase 2 ENACT trial, evaluating enzalutamide monotherapy vs active surveillance in patients with low- or intermediate-risk localized prostate cancer.

Joseph Renzulli, MD, discusses...

09/12/2022

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology